Regeneron Pharmaceuticals, Inc.
ANTI-PCSK9 ANTIBODIES

Last updated:

Abstract:

An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin/kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and/or with little or no measurable effect on liver function, as determined by ALT and AST measurements.

Status:
Application
Type:

Utility

Filling date:

28 Jan 2021

Issue date:

19 Aug 2021